Suggested Study as a Treatment Protocol for Coronavirus

 [1] Caly, L.; Druce, J.D.; Catton, M.G.; Jans, D.A. & Wagstaff, K.M.,"The FDA-   approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro", Antiviral Res. 104:(2020) 787-810

 [2] Lim, Y.X.; Ng, Y.L.; Tam, J.P. & Liu, D.X. ,"Human Coronaviruses: A review of Virus-Host interactions", Diseases, 4: (2016) 120-128

[3] Zhu, N.; Zhang, D.; Wang, W.; Li, X.; Yang, B.; Song, J.; Zhao, X.; Huang, B.; Shi, W.& Lu, R.,"A Novel coronavirus from patients with pneumonia in china", N. Engl. J. Med., 12: ( 2019)  651–658

[4[ Drosten, C.; Gunther, S.; Preiser, W.; van der Werf, S.; Brodt, H.R.; Becker, S.; Rabenau, H.; Panning, M.; Kolesnikova, L. & Fouchier, R.A.,"Identification of a novel coronavirus in patients with severe acute respiratory syndrome", N. Engl. J. Med.,348: .( 2003)1967–1976.

[5] Zaki, A.M.; van Boheemen, S.; Bestebroer, T.M.; Osterhaus, A.D. & Fouchier, R.A., "Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia", N. Engl. J. Med., 367: (2012) 1814–1820

[6] Fehr, A.R. & Perlman, S. ,"An overview of their replication and pathogenesis" Methods Mol. Biol., 1282: (2015) 1–23.

[7] Bosch, B.J.; van der Zee, R.; de Haan, C.A. & Rottier, P.J.,"The coronavirus spike protein is a class I virus fusion protein: Structural and functional characterization of the fusion core complex", J. Virol, 77: (2003) 8801–8811.

[8] Izaguirre,G.,"the Proteolytic Regulation of Virus Cell Entry by Furin and Other Proprotein Convertases",Viruses, 11: (2019) 837-855

[9] Bosch, B.J.; Bartelink, W. & Rottier, P.J. ,"Cathepsin L functionally cleaves the severe acute respiratory syndrome coronavirus class I fusion protein upstream of rather than adjacent to the fusion peptide", J. Virol.,82: (2008) 8887–8890

 [10] Nal, B.; Chan, C.; Kien, F.; Siu, L.; Tse, J.; Chu, K.; Kam, J.; Staropoli, I.; Crescenzo-Chaigne, B.& Escriou, N.,"Differential maturation and subcellular localization of severe acute respiratory syndrome coronavirus surface proteins S, M and E., J. Gen. Virol. 86: (2005) 1423–1434

[11] Siu, Y.L.; Teoh, K.T.; Lo, J.; Chan, C.M.; Kien, F.; Escriou, N.; Tsao, S.W.; Nicholls, J.M.; Altmeyer, R.& Peiris, J.S., "The M, E, and N structural proteins of the severe acute respiratory syndrome coronavirus are required for assembly, tracking, and release of virus-like particles" J. Virol., 82: ( 2008) 11318–11330.

 [12] Hurst, K.R.; Koetzner, C.A. & Masters, P.S. ,"Identification of in vivo-interacting domains of the murine coronavirus nucleocapsid protein"J. Virol, 83: (2009) 7221–7234.

 [13] Klausegger, A.; Strobl, B.; Regl, G.; Kaser, A.; Luytjes, W.& Vlasak, R. ,"Identification of a coronavirus hemagglutinin-esterase with a substrate specificity different from those of influenza C virus and bovine coronavirus"J. Virol.,73: (2009) 3737–3743.

[14] Savarino, A.; Boelaert ,J.R.; Cassone, A.; Majori, G.& Cauda, R.,"Effects of chloroquine on viral infections: an old drug against today’s diseases? Lancet Infect "Dis.,3 : (2003) 722-733

[15] Muhammad, A .S. ; Suliman ,K. ; Abeer ,K. ;Nadia B. ; Rabeea,S.,"COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses "Journal of Advanced Research ,24: (2020) 91–98

[16] Shereen, M.A.; Suliman, K.; Abeer, K.; Nadia, B. Rabeea, S. ,"COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses" Journal of Advanced Research ,24: (2020)  91–98

[17] Liu, J.; Cao ,R.; Xu ,M.; Wang, X.; Zhang, H.; Hu ,H.," Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro" Cell Discov,6: (2020) 16-29

[18] Wang, M.; Cao, R.; Zhang, L.; Yang, X.; Liu, J. & Xu, M.,"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro"Cell Res., 30: (2020)269-277.

 [19] White, .N.J.; Watson, J.A.; Hoglund, R.M.; Chan, X.H.; Cheah, P.Y. & Tarning, J.," COVID-19 prevention and treatment: a critical 707 analysis of chloroquin hydroxychloroquine clinical pharmacology"PLOS Medicine, (2020)  in press.

[20] World Health Organization, (2015)

[21] Conan, N.J. ,"The treatment of hepatic amebiasis with chloroquine",The American journal of medicine,  623 : (1949)309–320.

[22] Borba , M.G.S. ; Val, F.F.A. ; Sampaio, V.S. ; Alexandre, M.A.A. ; Melo, G.C. ; Brito, M. ; Mourão, M.P.G. ; Brito-Sousa, J.D. ; Baía-da-Silva, D. ; Guerra, M.V.F. ; Hajjar, .LA. ; Pinto, R.C. ; Balieiro, A.A.S. ; Pacheco, A.G.F. ; Santos, J.D.O. ;  Naveca, F.G. ,"Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS595 CoV-2) infection: A randomized clinical trial",JAMA Network Open. 4: (2020)342–355

 [23] Riou, B.;Barriot ,P.; Rimailho, A.& Baud, F.J.,"Treatment of severe chloroquine poisoning", N. Engl.J. Med., 318: (1988) 1–6.

[24] Mégarbane, B.; Bloch, V.; Hirt, D.; Debray,M.; Résiére, D.; Deye, N.& Baud, F.J.," Blood concentrations are better predictors of chioroquine poisoning severity than plasma concentrations: a prospective study with modeling of the concentration/effect relationships", Clin. Toxicol. 48: (2003) 904–915

[25] de Graaf, C.; Kooistra, A.J.; Vischer, H.F.;Katritch, V.; Kuijer, M.; Shiroishi, M.; Iwata, S.; Shimamura ,T.;Stevens, R.C.; de Esch, I.J.&Leurs, R. ,"Crystal structure-based virtual screening for fragment-like ligands of the human histamine H(1) receptor", J. Med.Chem., 54 : (2011) 8195–206

[26] Khilnani, G. & Khilnani, A.K. ,"Inverse agonism and its therapeutic significance",Ind. J. Pharmacol., 43 : (2011) 492–501

[27] Wiggins, S.A. & Griebling,T.,"Urinary Incontinence", Landon Center on Aging. Archived from the original on 2011, Retrieved ,14: (2011) 07-19

[28] van den Kommer, T. N.; Dik, M. G.; Comijs, H. C.; Jonker, C.& Deeg ,D. J. H.," Homocysteine and inflammation: predictors of cognitive decline in older persons. Neurobiology of Aging, J.neurobiolaging 31: ( 2010)1700–1709.

[29] Wu, J. T. ,"Circulating homocysteine is an inflammation marker and a risk factor of life-threatening inflammatory diseases "J. Biomed. Lab. Sci., 19: (2007)107–111

 [30] Li, M.; Chen, J.; Li, Y.-S.; Feng ,Y.-B.; Gu, X.& Shi, C.Z. ,"Folic acid reduces adhesion molecules VCAM-1 expession in aortic of rats with hyperhomocysteinemia", International Journal of Cardiology,106: (2006)285–288

 [31] Clarke, R., L.; Daly, K.; Robinson, E.; Naughten, S.; Cahalane, B.; & Graham, I. ,"Hyperhomocysteinemia: an independent risk factor for vascular disease", N. Engl. J. Med. 324: (1991) 1149–1155.

 [32] Johan, B.; Ubbink, A.; Annatjie, V.; Rhena, D.; Robert, H.; & Vermaak,E.,"Vitamin B-6 and Homocysteine Metabolism",J. Clin. Invest., 98: (1996) 177–184

[33] Soedamah, M.S.S.; Chaturvedi, N.; Teerlink, T.; Idzior, W.R.; Fuller ,J.H.& Stehouwer, C.D.A.," Plasma homocysteine and microvascular and macrovascular complications in type 1 diabetes: A cross-sectional nested case control study", J Intern Med., 258: (2005) 450–459

[34] Looker, H.C.; Fagot, C.A.; Gunter, E.W.; Pfeiffer, C.M.; Narayan ,K.M.V.& Knowler, W.C. ,"Homocysteine as a risk factor for nephropathy and retinopathy in Type 2 diabetes", Diabetologia, 46: (2003)766–772

[35] Yuecel, I.; Yeucel, G. & Mueftueoglu, F. ,"Plasma homocysteine levels in noninsulin-dependent diabetes mellitus with retinopathy and neovascular glaucoma",Int Ophthalmol.,25: (2004)201–205

[36] Yoshikaw, T. ,"Histamine N-Methyltransferase in the Brain",Int. J. Mol. Sci., 20: (2019)  737-758

[37] Ede, G. ,"Histamine Intolerance: why freshness matters",J. Evol. Health2 ,1: (2020) 23-39

[38] McEwen, B. S. & Wingfield, J. C. ,"the concept of allostasis in biology and biomedicine", Horm Behav 43: (2003) 2–15

[39] Remage-Healey, L. & Romero, L. M. ,"Daily and seasonal variation in response to        stress in captive starlings Sturnus, glucose", Gen Comp Endocrinol. 119: (2000) 60–68.

[40] Hill, R.A.; Makin, H.L.J.; Kirk, D.N. & Murphy. G.M.,"Dictionary of Steroids",189: (1991) 978-990.

[41] Romeo, R. D., Tang, A. C., & Sullivan, R. M.,"Early life experiences: Enduring behavioral, neurological and endocrinological consequences. In D. W. Pfaff& A. M. Etgen (Eds.)",Molecular mechanisms of hormone actions on behavior.12: (2009)543-572.

[42] Eduardo, N.; Cozza, B.; Matkovic, C. ,"in Handbook of Hormones", (2016) : 529-530

[43] Priti, N.; & Emily M. ,"Meclizine: Safety and Efficacy in the Treatment and Prevention of Motion Sickness", Clinical Medicine Insights: Therapeutics,3: (2011) 179-183